SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,787,405 | +7.6% | 355,002 | +17.3% | 0.00% | 0.0% |
| Q2 2023 | $9,098,470 | -25.7% | 302,677 | -10.5% | 0.00% | 0.0% |
| Q1 2023 | $12,251,827 | +2.0% | 338,168 | +0.4% | 0.00% | 0.0% |
| Q4 2022 | $12,014,548 | +5.9% | 336,825 | +0.5% | 0.00% | 0.0% |
| Q3 2022 | $11,343,000 | +21.5% | 335,093 | +3.8% | 0.00% | 0.0% |
| Q2 2022 | $9,339,000 | -42.7% | 322,945 | -35.9% | 0.00% | -50.0% |
| Q1 2022 | $16,295,000 | +4.5% | 504,173 | -5.7% | 0.00% | 0.0% |
| Q4 2021 | $15,597,000 | +21.3% | 534,919 | +10.9% | 0.00% | +100.0% |
| Q3 2021 | $12,862,000 | -28.2% | 482,258 | -17.1% | 0.00% | -50.0% |
| Q2 2021 | $17,920,000 | +19.0% | 582,051 | +1.2% | 0.00% | 0.0% |
| Q1 2021 | $15,062,000 | +13.2% | 575,363 | +8.8% | 0.00% | 0.0% |
| Q4 2020 | $13,306,000 | +3.3% | 528,853 | -14.5% | 0.00% | 0.0% |
| Q3 2020 | $12,883,000 | +2.1% | 618,225 | +16.4% | 0.00% | 0.0% |
| Q2 2020 | $12,619,000 | +60.4% | 531,324 | +21.5% | 0.00% | +100.0% |
| Q1 2020 | $7,867,000 | -26.5% | 437,333 | -3.1% | 0.00% | -50.0% |
| Q4 2019 | $10,705,000 | -37.5% | 451,260 | -27.6% | 0.00% | -33.3% |
| Q3 2019 | $17,137,000 | -31.5% | 623,604 | -17.5% | 0.00% | -25.0% |
| Q2 2019 | $25,023,000 | -6.6% | 756,170 | -1.1% | 0.00% | 0.0% |
| Q1 2019 | $26,778,000 | +14.1% | 764,245 | +8.2% | 0.00% | 0.0% |
| Q4 2018 | $23,460,000 | -29.1% | 706,227 | +7.4% | 0.00% | -20.0% |
| Q3 2018 | $33,100,000 | +6.5% | 657,407 | +26.6% | 0.01% | 0.0% |
| Q2 2018 | $31,086,000 | +103.4% | 519,395 | +55.7% | 0.01% | +66.7% |
| Q1 2018 | $15,282,000 | +34.4% | 333,632 | +16.9% | 0.00% | +50.0% |
| Q4 2017 | $11,370,000 | -42.3% | 285,346 | -42.1% | 0.00% | -33.3% |
| Q3 2017 | $19,722,000 | +29.9% | 493,069 | +40.0% | 0.00% | 0.0% |
| Q2 2017 | $15,185,000 | +33.7% | 352,306 | -2.9% | 0.00% | +50.0% |
| Q1 2017 | $11,361,000 | +37.2% | 362,952 | +10.7% | 0.00% | 0.0% |
| Q4 2016 | $8,280,000 | +1.8% | 327,883 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $8,135,000 | +6.5% | 328,952 | -12.3% | 0.00% | 0.0% |
| Q2 2016 | $7,640,000 | +26.9% | 375,010 | -5.0% | 0.00% | +100.0% |
| Q1 2016 | $6,020,000 | +14.0% | 394,753 | +0.5% | 0.00% | 0.0% |
| Q4 2015 | $5,280,000 | +9.2% | 392,922 | +14.0% | 0.00% | 0.0% |
| Q3 2015 | $4,834,000 | +730.6% | 344,520 | +904.8% | 0.00% | – |
| Q2 2015 | $582,000 | +131.9% | 34,286 | +65.1% | 0.00% | – |
| Q1 2015 | $251,000 | +230.3% | 20,773 | +125.8% | 0.00% | – |
| Q4 2014 | $76,000 | -71.0% | 9,200 | -69.5% | 0.00% | – |
| Q3 2014 | $262,000 | -85.6% | 30,182 | -81.8% | 0.00% | -100.0% |
| Q2 2014 | $1,814,000 | -59.8% | 165,600 | -67.2% | 0.00% | -50.0% |
| Q1 2014 | $4,515,000 | +6350.0% | 505,028 | +5314.1% | 0.00% | – |
| Q4 2013 | $70,000 | +59.1% | 9,328 | +55.6% | 0.00% | – |
| Q3 2013 | $44,000 | -67.2% | 5,994 | -71.2% | 0.00% | – |
| Q2 2013 | $134,000 | – | 20,827 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |